Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of October 2023. The report, dated October 5, 2023, incorporates by reference a press release (Exhibit 99.1) and is signed by Mondher Mahjoubi, Chairman of the Executive Board and CEO.
Key Financial Metrics
The filing text provided does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or details on unusual items. The document serves primarily as a cover for the referenced press release.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) referenced in this filing for specific operational or clinical updates.
- Verify the company's current cash position and burn rate in the most recent Form 20-F or quarterly report, as this 6-K contains no financial figures.
- Confirm the status of ongoing clinical trials or regulatory milestones mentioned in the October 5, 2023 press release.